Radium bromatum pills

Phase 3Small molecule

CCentre Hospitalier Universitaire de Saint Etienne

Radium bromatum pills is one of 11 small molecule programs targeting Radiodermatitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

RadiodermatitisActive, not recruiting

RadiodermatitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

14 competitors in Radiodermatitis

#DrugCompanyPhaseTrials

Golytely

Bactroban

Betamethasone Valerate

GSK

Approved

1 4

Sterile Urea

Pfizer

Phase 3

1 5

Olive Oil

AstraZeneca

Approved

1 6

Asmanex

Peridex

Curcumin

Levophed

GGeneral Hospital of Ningxia Medical University

Phase 1

1 10

Urea Dose C

UUniversity of Brasilia

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Radiodermatitis1 trial

Phase III Trial Evaluating Radium Bromatum Homeopathic Treatment Efficacy on Radiodermatitis Prevention and Treatment for Breast Cancer Women

Completed·—·Phase 3·NCT03753776·232 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Radium bromatum pills. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Radium bromatum pills compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Radium bromatum pills. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Centre Hospitalier Universitaire de Saint Etienne company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCentre Hospitalier Universitaire de Saint Etienne

Radium bromatum pills

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Radiodermatitis1 trial

References

Drug Info

Quick Facts

Related News